New hope for tough blood cancers: drug added to transplant process
NCT ID NCT03613532
Summary
This study is testing the safety of adding a drug called venetoclax to the standard treatment given before a bone marrow transplant for people with high-risk blood cancers like AML and MDS. It also tests giving venetoclax with other drugs after the transplant to try to prevent the cancer from coming back. The main goal is to find safe doses and schedules for this new approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.